XARELTO
PeakNDAORALTABLET
Approved
Nov 2011
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2123
Data completeness
5/8 — Partial
IRA Negotiated
XARELTO by Johnson & Johnson is fxa. Approved for deep vein thrombosis (dvt), pulmonary embolism (pe), which may lead to pe in adult patients undergoing knee and 17 more indications. First approved in 2011.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XARELTO is an oral small-molecule anticoagulant approved in 2011 for thromboembolism prevention and treatment. The specific mechanism of action and indications are not detailed in available data, but the product is a cornerstone of Johnson & Johnson's cardiovascular portfolio. It represents a peak lifecycle product with sustained commercial significance.
$6.3BPart D
PeakStable
Peak-stage product with 6.6M annual claims and $6.3B spending indicates large, mature team with stable headcount across commercial, medical, and regulatory functions.
Mechanism of Action
FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban…
Indications (20)
Worked on XARELTO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.